Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous versus subcutaneous immunoglobulin therapy in multifocal motor neuropathy
NL-OMON31197Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2007
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Gamimune-N and polyvalent human immunoglobulin in multifocal motor neuropathy (MMN), sponsored by Amsterdam University Medical Center. Planned start May 2007; status: not yet recruiting.
02
Drugs
Gamimune-Npolyvalent human immunoglobulin
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NL-OMON31197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31197.